p53 Review Article

You have free access to this content

TP53 and breast cancer†

  1. Anne-Lise Børresen-Dale*

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10174

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 292–300, March 2003

Additional Information

How to Cite

Børresen-Dale, A.-L. (2003), TP53 and breast cancer. Hum. Mutat., 21: 292–300. doi: 10.1002/humu.10174

Author Information

  1. Department of Genetics, Institute for Cancer Research, The University Hospital, The Norwegian Radium Hospital, Montebello, Oslo, Norway

*Department of Genetics, Institute for Cancer Research, The University Hospital The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (133K)

REFERENCES

  • Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. 1996. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811–814.
  • Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. 2000. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 6:3923–3931.
  • Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL. 1993. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68:540–548.
  • Andersen TI, Børresen AL. 1995. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol 4:203–211.
  • Barbareschi M. 2002. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: a review of the literature involving over 9,000 patients. Appl Immunohistochem 4:106–116.
  • Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. 1995. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029–1034.
  • Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA. 1998. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77:1130–1136.
  • Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG. 2000. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60:2155–2162.
  • Beroud C, Soussi T. 1998. p53 gene mutation: software and database. Nucleic Acids Res 26:200–204.
  • Beroud C, Soussi T. 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176–181.
    Direct Link:
  • Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SS. 2000. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 89:32–38.
    Direct Link:
  • Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S. 1995. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14:71–75.
    Direct Link:
  • Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF. 1994. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 73:2147–2156.
    Direct Link:
  • Conway K, Edmiston SN, Cui L, Drouin SS, Pang J, He M, Tse CK, Geradts J, Dressler L, Liu ET, Millikan R, Newman B. 2002. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 62:1987–1995.
  • de Witte HH, Foekens JA, Lennerstrand J, Smid M, Look MP, Klijn JG, Benraad TJ, Berns EM. 1996. Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 69:125–130.
    Direct Link:
  • Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. 2001a. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst. 93:700–704.
  • Done SJ, Arneson CR, Ozcelik H, Redston M, Andrulis IL. 2001b. P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Res Treat 65:111–118.
  • Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. 1999. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854.
  • Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, William L. 1993. McGuire memorial symposium. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 27:95–102.
  • Falette N, Paperin MP, Treilleux I, Gratadour AC, Peloux N, Mignotte H, Tooke N, Lofman E, Inganas M, Bremond A, Ozturk M, Puisieux A. 1998. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 58:1451–1455.
  • Ferlay J, Bray F, Pisane Parkin DM. 2001. Cancer incidence, mortality and prevalence worldwide. Globocan 2000 (CD-ROM). IARC Press.
  • Gasco M, Yulug IG, Crook T. 2003. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat 21:301–306.
    Direct Link:
  • Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Borresen-Dale AL. 2001. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505–2512.
  • Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. 2001. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61:4092–4097.
  • Gretarsdottir S, Tryggvadottir L, Jonasson JG, Sigurdsson H, Olafsdottir K, Agnarsson BA, Ogmundsdottir H, Eyfjord JE. 1996. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 74:555–561.
  • Gudmundsdottir K, Tryggvadottir L, Eyfjord JE. 2001. GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 10:1169–1173.
  • Hartmann A, Blaszyk H, Kovach JS, Sommer SS. 1997. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13:27–33.
  • Hill KA, Sommer SS. 2002. p53 as a mutagen test in breast cancer. Environ Mol Mutagen 39:216–227.
    Direct Link:
  • Ho GH, Calvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, Van Zee KJ. 2000. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 89:2153–2160.
    Direct Link:
  • Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Seshadri R. 1998. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 4:1597–1602.
  • Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Eynstein LP, Kaaresen R, Gray JW. 2001. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci 98:7952–7957.
  • Jansson T, Inganas M, Sjogren S, Norberg T, Lindgren A, Holmberg L, Bergh J. 1995. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13:2745–2751.
  • Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R. 2000. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50–56.
  • Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A. 2002. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev 11:127–130.
  • Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. 1996. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci 93:1093–1096.
  • Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlbock M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R. 1999. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian breast cancer study group. Eur J Cancer 35:398–405.
  • Langerød A, Bukholm IRK, Bregård A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale A-L. 2002. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epid Biomarker and Prev 11:1684–1688.
  • Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 3 250:1233–1238.
  • Nedelcheva KV, Andersen TI, Erikstein B, Geitvik G, Skovlund E, Nesland JM, Borresen-Dale AL. 1998. Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics 8:441–447.
  • Norberg T, Lennerstrand J, Inganas M, Bergh J. 1998. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 79:376–383.
    Direct Link:
  • Norberg T, Klaar S, Karf G, Nordgren H, Holmberg L, Bergh J. 2001. Increased p53 mutation frequency during tumor progression–results from a breast cancer cohort. Cancer Res 61:8317–8321.
  • Olivier M, Hainaut P. 2001. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol 11:353–360.
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614.
    Direct Link:
  • Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. 2000. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 39:327–333.
  • Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747–752.
  • Pharoah PD, Day NE, Caldas C. 1999. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80:1968–1973.
  • Pollack JR, Sørlie T, Perou CM, Res C, Eisen M, Jeffrey S, Johnsen H, Lønning PE, Botstein D, Børresen-Dale AL, Brown PA. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. PNAS 99:12963–12968.
  • Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. 2000. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 6:443–451.
  • Powell BL, Bydder S, Grieu F, Gnanasampanthan G, Elsaleh H, Seshadri R, Berns EM, Iacopetta B. 2001. Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients. Breast Cancer Res Treat 69:65–68.
  • Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B. 2002. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 23:311–315.
  • Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. 1993. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 85:1765–1767.
  • Saitoh S, Cunningham J, De Vries EM, McGovern RM, Schroeder JJ, Hartmann A, Blaszyk H, Wold LE, Schaid D, Sommer SS. 1994. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9:2869–2875.
  • Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. 1996. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 69:135–141.
    Direct Link:
  • Shao ZM, Wu J, Shen ZZ, Nguyen M. 2001. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 7:2222–2227.
  • Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. 1995. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55:1485–1490.
  • Simao TA, Ribeiro FS, Amorim LMF, Albano RM, Andrea-Serpa MJ, Cardoso LEB, Mendonca GAS, deMoura-Gallo CV. 2002. TP53 mutations in breast cancer tumors of patients from Rio De Janeiro, Brazil: association with risk factors and tumor characteristics. Int J Cancer 101:69–73.
    Direct Link:
  • Sivaraman L, Conneely OM, Medina D, O'Malley BW. 2001. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. PNAS 98:12379–12384.
  • Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJ, Hahnel R, Robbins PD. 1997. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 74:642–647.
    Direct Link:
  • Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98:10869–10874.
  • Sørlie T, Børresen-Dale A-L, Botstein D. 2003. Expression profiling of breast cancer: from molecular portraits to clinical utility. BrennanC, DuganDJ, Editors. In: Oncogenomics: molecular approaches to cancer. Wiley & Sons. In press.
  • Soussi T, Dehouche K, Beroud C. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15:105–113.
    Direct Link:
  • Soussi T, Beroud C. 2001. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240.
  • Thorlacius S, Borresen AL, Eyfjord JE. 1993. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53:1637–1641.
  • Thorlacius S, Thorgilsson B, Bjornsson J, Tryggvadottir L, Borresen AL, Ogmundsdottir HM, Eyfjord JE. 1995. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 31A:1856–1861.
  • Toyooka S, Tsuda T, Gazdar AF. 2003. The TP53 gene, tobacco exposure and lung cancer. Hum Mutat 21:229–239.
    Direct Link:
  • Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S. 1998. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 48:21–32.
  • Vähäkangas K. 2003. TP53 mutations in workers exposed to occupational carcinogens. Hum Mutat 21:240–251.
    Direct Link:
  • Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ogmundsdottir HM, Eyfjord JE. 1997. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis 105:121–130.
  • Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, Evans DG, Birch JM. 1997. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14:865–871.
  • Weston A, Wolff MS, Morabia A. 1998. True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 102:153–154.
Get PDF (133K)